Patents Assigned to Aqualung Therapeutics Corp.
  • ANTI-HUMAN NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) ANTIBODIES
    Publication number: 20230220113
    Abstract: Anti-nicotinamide phosphoribosyltransferase (NAMPT) antibodies, or antigen binding fragments thereof, are described, as well as methods for treating a subject having a (NAMPT)-associated local and/or systemic inflammatory disorder.
    Type: Application
    Filed: September 9, 2022
    Publication date: July 13, 2023
    Applicant: AQUALUNG THERAPEUTICS CORP.
    Inventors: JOE G.N. GARCIA, DARRAGH MACCANN
  • Anti-human nicotinamide phosphoribosyltransferase (NAMPT) antibodies
    Patent number: 11466099
    Abstract: Anti-nicotinamide phosphoribosyltransferase (NAMPT) antibodies, or antigen binding fragments thereof, are described, as well as methods for treating a subject having a (NAMPT)-associated local and/or systemic inflammatory disorder.
    Type: Grant
    Filed: October 11, 2021
    Date of Patent: October 11, 2022
    Assignee: Aqualung Therapeutics Corp.
    Inventors: Joe G. N. Garcia, Darragh Maccann